Vericel Corporation (VCEL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vericel Corporation (VCEL)
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Key Insights
Critical company metrics and information
Share Price
$56.37Market Cap
$2.78 BillionTotal Outstanding Shares
49.36 Million SharesTotal Employees
314Dividend
No dividendIPO Date
February 4, 1997SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.vcel.com
Historical Stock Splits
If you bought 1 share of VCEL before October 16, 2013, you'd have 0.05 shares today.
Execution Date | Split Amount |
---|---|
October 16, 2013 | 1-for-20 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $46.01 Million |
Net Cash Flow From Operating Activities, Continuing | $46.01 Million |
Net Cash Flow, Continuing | $-13.21 Million |
Net Cash Flow From Financing Activities, Continuing | $13.25 Million |
Net Cash Flow From Investing Activities, Continuing | $-72.47 Million |
Net Cash Flow | $-13.21 Million |
Net Cash Flow From Investing Activities | $-72.47 Million |
Net Cash Flow From Financing Activities | $13.25 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Gross Profit | $162.12 Million |
Basic Average Shares | $48.69 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Benefits Costs and Expenses | $222.20 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations After Tax | $3.55 Million |
Revenues | $226.84 Million |
Net Income/Loss | $3.55 Million |
Diluted Earnings Per Share | $0.07 |
Cost Of Revenue | $64.73 Million |
Selling, General, and Administrative Expenses | $138.57 Million |
Diluted Average Shares | $48.69 Million |
Income/Loss From Continuing Operations Before Tax | $4.65 Million |
Operating Expenses | $163.34 Million |
Income Tax Expense/Benefit | $1.10 Million |
Basic Earnings Per Share | $0.07 |
Research and Development | $24.77 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $-1.23 Million |
Net Income/Loss Attributable To Parent | $3.55 Million |
Costs And Expenses | $222.20 Million |
Nonoperating Income/Loss | $5.88 Million |
Net Income/Loss Available To Common Stockholders, Basic | $3.55 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $390.40 Million |
Liabilities And Equity | $390.40 Million |
Equity | $257.47 Million |
Inventory | $15.76 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $132.93 Million |
Other Current Liabilities | $17.38 Million |
Current Assets | $190.52 Million |
Wages | $3.09 Million |
Other Current Assets | $174.76 Million |
Noncurrent Assets | $199.88 Million |
Noncurrent Liabilities | $91.59 Million |
Current Liabilities | $41.35 Million |
Accounts Payable | $20.88 Million |
Equity Attributable To Parent | $257.47 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.